Oral immunotherapy for treatment of peanut allergy

Research output: Contribution to journalReview articlepeer-review


The US Food and Drug Administration's approval of a peanut oral immunotherapy product in January 2020 is a landmark development in the field of food allergy therapy. While food allergy prevalence has been increasing, this product is the first approved therapy for food allergy. Oral immunotherapy has many similarities to subcutaneous immunotherapy and drug desensitization protocols, but does not lead to sustained unresponsiveness. The studies leading to approval of the Palforzia product demonstrated increase in the amount of peanut protein able to be consumed, with 67 of subjects randomized to the treatment arm able to consume 600 mg of peanut protein in double-blind placebo-controlled food challenge at study exit. However, side effects are an important consideration, and dropout rates in studies of Palforzia ranged from 11 to 21. Postmarketing surveillance of this product will be critical in assessing its long-term risks and benefits.

Original languageEnglish (US)
Pages (from-to)1152-1155
Number of pages4
JournalJournal of Investigative Medicine
Issue number6
StatePublished - Aug 1 2020


  • drug discovery
  • drug-related side effects and adverse reactions
  • immune tolerance

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Oral immunotherapy for treatment of peanut allergy'. Together they form a unique fingerprint.

Cite this